# Anti-FGF23 (Burosumab) in Adult Patients With XLH

> **NCT04695860** · PHASE3 · COMPLETED · sponsor: **Wuerzburg University Hospital** · enrollment: 36 (actual)

## Conditions studied

- X-linked Hypophosphatemia

## Interventions

- **DRUG:** Burosumab

## Key facts

- **NCT ID:** NCT04695860
- **Lead sponsor:** Wuerzburg University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695860, "Anti-FGF23 (Burosumab) in Adult Patients With XLH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04695860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*